Aura Biosciences annual return on equity
2021
2022
2023
2024
2025
Aura Biosciences Return on Equity (ROE) Growth & History (AURA)
Aura Biosciences's return on equity was −73.52% for fiscal 2025.
View full Aura Biosciences company overviewAura Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −73.52% | −27.51 pp |
| 2024 | 2024-12-31 | −46.01% | −9.75 pp |
| 2023 | 2023-12-31 | −36.26% | −2.48 pp |
| 2022 | 2022-12-31 | −33.78% | +127.91 pp |
| 2021 | 2021-12-31 | −161.69% | — |
Aura Biosciences quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −21.60% | −3.74 pp |
| Q1 2026 | 2026-03-31 | −27.59% | −7.96 pp |
| Q4 2025 | 2025-12-31 | −17.41% | −1.59 pp |
| Q3 2025 | 2025-09-30 | −15.77% | −4.28 pp |
| Q2 2025 | 2025-06-30 | −17.86% | −7.70 pp |
| Q1 2025 | 2025-03-31 | −19.64% | −10.57 pp |
| Q4 2024 | 2024-12-31 | −15.82% | −4.10 pp |
| Q3 2024 | 2024-09-30 | −11.49% | +0.14 pp |
| Q2 2024 | 2024-06-30 | −10.16% | +0.39 pp |
| Q1 2024 | 2024-03-31 | −9.07% | +0.23 pp |
| Q4 2023 | 2023-12-31 | −11.72% | −1.06 pp |
| Q3 2023 | 2023-09-30 | −11.64% | +1.39 pp |
| Q2 2023 | 2023-06-30 | −10.56% | −0.59 pp |
| Q1 2023 | 2023-03-31 | −9.29% | −0.55 pp |
| Q4 2022 | 2022-12-31 | −10.66% | +98.58 pp |
| Q3 2022 | 2022-09-30 | −13.03% | — |
| Q2 2022 | 2022-06-30 | −9.97% | — |
| Q1 2022 | 2022-03-31 | −8.75% | — |
| Q4 2021 | 2021-12-31 | −109.24% | — |
Aura Biosciences return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Aura Biosciences's return on equity increased from −161.69% to −73.52%, a change of +88.18 percentage points. The latest reported quarter, Q2 2026, shows −21.60%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aura Biosciences source filings ↗